Most business owners have real-time visibility into their company’s cash position, pipeline health, and key risks. Almost none of them have equivalent visibility into the four biological processes most likely to end their life early — or permanently limit their function.
There is a particular kind of meeting that investors and founders both know well: the one where someone finally says out loud what the data has been suggesting for months. The numbers were there. The signals were there. But because nothing had visibly broken yet, no one acted. By the time the conversation became urgent, the options had narrowed considerably.
This pattern — delayed recognition of slow-moving risk — is not a failure of intelligence. It is a feature of how human beings process information. We respond to immediate signals, not to trend lines. We intervene in crises, not in trajectories.
The same cognitive failure plays out in health. The four conditions most likely to kill or disable an otherwise high-functioning person in the developed world — cardiovascular disease, cancer, Alzheimer’s disease, and metabolic dysfunction — do not announce themselves. They build slowly, silently, over years or decades, before crossing the threshold into clinical symptoms. By the time a standard health check detects them, the underlying biology has often been deteriorating for a very long time.
Physician and longevity researcher Peter Attia calls these four conditions “the Horsemen.” Understanding how they work — and more specifically, when they begin — is the foundation of any serious longevity strategy.
Horseman One: Cardiovascular Disease
Heart disease remains the leading cause of death across most of the developed world. The conventional understanding frames it as a condition that “strikes” — a sudden event, a crisis, a cardiac arrest. The biology is entirely different.
Atherosclerosis, the underlying process behind most cardiovascular events, is a decades-long accumulation of plaques in arterial walls, driven by lipoproteins — primarily a particle called apolipoprotein B, or apoB. Every time an apoB-containing particle embeds itself in the arterial wall and triggers an inflammatory response, plaque grows slightly. This process typically begins in the twenties or thirties. It does not become symptomatic until something ruptures — usually in the fifties, sixties, or seventies.
The critical insight Attia draws from the research is that the total cumulative exposure to apoB over a lifetime matters far more than any single measurement in a given year. A person with moderately elevated apoB who does nothing about it for thirty years faces a fundamentally different risk profile than someone who intervenes early. The standard lipid panel most physicians order — total cholesterol, LDL, HDL, triglycerides — does not capture this with sufficient precision. ApoB does.
For a founder, the implication is direct: your cardiovascular risk is not being accurately tracked by your annual physical. And the window during which lifestyle and pharmacological intervention can meaningfully change your lifetime trajectory is wide — but it is not infinite.
Horseman Two: Cancer
Cancer is the most feared of the four Horsemen, in part because it feels like the most random. But the biology of cancer is, at its core, a story about accumulated genetic damage — errors that accumulate in cells over time, eventually producing a cell that escapes the normal regulatory mechanisms and begins dividing uncontrollably.
Two things follow from this. First, the risk of cancer increases substantially with age, not because aging itself is carcinogenic but because the accumulation of cellular errors takes time. Second, the earlier a cancer is detected, the more options exist for treatment, and the better the outcomes. The difference in survival between a Stage I and Stage IV cancer diagnosis is, in many cancers, measured in decades.
Current standard screening protocols are largely reactive: they look for cancers that have already formed and reached a detectable size. Emerging technologies — particularly multi-cancer early detection tests, which screen blood for cancer-associated signals — are beginning to shift this, but they are not yet widely adopted in clinical practice.
What individuals can influence is the environment in which cancer develops. Metabolic dysfunction, chronic inflammation, visceral fat accumulation, and poor sleep quality all create conditions that make cellular damage more likely and immune surveillance less effective. These are not abstract factors: they are measurable, modifiable, and directly connected to behavioral choices.
Horseman Three: Alzheimer’s Disease and Neurodegeneration
No disease generates more fear among high-functioning people than Alzheimer’s. The prospect of cognitive decline — the erosion of precisely the capabilities that define a life in business, strategy, and relationships — is, for most founders, more frightening than physical decline.
What the research reveals is both sobering and actionable. Alzheimer’s disease begins its biological progression fifteen to twenty years before the first observable symptom. The plaques and tangles that characterize the disease — amyloid and tau proteins accumulating in the brain — have typically been building for decades by the time a person first notices memory lapses.
Genetic risk is real and worth knowing. The APOE gene comes in several variants; carriers of two copies of the e4 variant face a significantly elevated risk of developing the disease. This is not a death sentence — many e4/e4 carriers never develop Alzheimer’s — but it is actionable information. Knowing your APOE genotype allows you to calibrate the intensity of preventive strategies accordingly.
More broadly, the same metabolic factors that drive cardiovascular disease — insulin resistance, inflammation, poor vascular health — also increase Alzheimer’s risk. The brain is a vascular organ. Its health is deeply entangled with cardiovascular health. Exercise, sleep quality, and metabolic function are among the most powerful levers available for reducing neurodegeneration risk. These are not alternative medicine claims; they are findings from mainstream neuroscience research.
Horseman Four: Metabolic Dysfunction
Type 2 diabetes is, in many respects, the silent engine driving the other three Horsemen. Insulin resistance — the impaired ability of cells to respond appropriately to insulin — precedes a formal diabetes diagnosis by years or decades. During that time, it is creating the conditions for cardiovascular damage, cancer risk elevation, and neuroinflammation.
The prevalence of metabolic dysfunction in the developed world is staggering, and it is not limited to people who are visibly overweight. Attia describes the concept of “TOFI” — thin outside, fat inside — individuals who appear metabolically healthy by conventional appearance but carry significant visceral fat and insulin resistance. The key markers for metabolic health — fasting glucose, insulin, triglycerides, waist circumference, and blood pressure — are straightforward to measure and often not part of a standard annual physical.
The reversibility of metabolic dysfunction, particularly in its earlier stages, is one of the most clinically significant findings in longevity research. Unlike the other Horsemen, which involve structural changes that are difficult or impossible to reverse, insulin resistance is highly responsive to behavioral intervention. Exercise, nutrition, and sleep quality can produce measurable improvements in insulin sensitivity within weeks.
The Portfolio View of Risk
The Horsemen do not operate in isolation. They interact, amplify each other, and share common upstream drivers. Visceral adiposity worsens insulin resistance, which accelerates arterial plaque formation, which increases cardiovascular risk, which also increases Alzheimer’s risk through vascular mechanisms. Poor sleep quality elevates cortisol, worsens insulin sensitivity, increases inflammation, and impairs the glymphatic system that clears amyloid from the brain.
A founder who manages their business risk in silos — treating each risk as independent and addressing them sequentially — is leaving enormous exposure on the table. The same is true of health. The most efficient longevity strategy addresses the shared root causes: metabolic health, inflammation, sleep, and physical capacity. Improving these factors simultaneously reduces risk across all four Horsemen.
The starting point is always the same: know where you actually stand. Not based on a routine checkup that was designed to catch acute disease, but based on a comprehensive picture of your biological risk factors, measured early enough that intervention is still maximally effective.
The Horsemen are slow. That is their danger — and also the source of your leverage against them.
The Blue connects science-backed longevity innovation with the capital and frameworks needed to scale it. This article is part of a series exploring the intersection of longevity science and high-performance leadership.